However, your health insurer may not cover these drugs unless you have an obesity-related medical problem, such as high cholesterol or high blood pressure
For patients using oral semaglutide to support weight losssometimes used off-label for this purposeearly changes like reduced appetite and modest weight reduction can appear in the first few weeks
However, we believe there should be no disparity in pharmaceutical advertising requirements between regulated entities," Durbin and Marshall wrote in the letter, dated Feb
Approval was based on clinical trials that involved over 5,000 overweight or obese individuals
Although preliminary findings indicate that GLP-1Ra causes modest bone mineral density reduction and enhances bone remodeling, favoring resorption similar to the effects of calorie restriction, further research is needed on fracture-related outcomes in people living with obesity